AP
GSK icon

Arlington Partners’s GSK GSK Stock Holding History

Arlington Partners’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$282K Buy
5,388
+1,006
+23% +$53.2K 0.51% 15
2026
Q1 		$242K Buy
+4,382
New +$237K 0.48% 21
2025
Q4 		– Sell
-125,748
Closed -$5.43M – 27
2025
Q3 		$5.43M Buy
125,748
+64,746
+106% +$2.53M 1.88% 8
2025
Q2 		$2.34M Buy
+61,002
New +$2.33M 0.86% 55
2023
Q3 		– Sell
-320
Closed -$11.4K – 503
2023
Q2 		$11.4K Buy
+320
New +$11.5K ﹤0.01% 454
2022
Q1 		– Sell
-416
Closed -$23K – 532
2021
Q4 		$23K Buy
+416
New +$21.6K 0.01% 354
2020
Q2 		– Sell
-98
Closed -$5K – 217
2020
Q1 		$5K Sell
98
-162
-62% -$8.64K ﹤0.01% 188
2019
Q4 		$15K Hold
260
– – 0.01% 179
2019
Q3 		$14K Hold
260
– – 0.01% 147
2019
Q2 		$13K Hold
260
– – 0.01% 192
2019
Q1 		$14K Hold
260
– – 0.01% 162
2018
Q4 		$12K Buy
+260
New +$12.8K 0.01% 166

Other funds holding GSK

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
KFP
Keystone Financial Planning Cleveland, Ohio $388M AUM 16.66% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
BB
Bell Bank Fargo, North Dakota $2.62B AUM 23.93% 1-Year Est. Return
KIC
Keating Investment Counselors Delray Beach, Florida $364M AUM 22.11% 1-Year Est. Return
GHAM
Gilman Hill Asset Management New Canaan, Connecticut $731M AUM 19.41% 1-Year Est. Return
AWAG
ARS Wealth Advisors Group St. Petersburg, Florida $1.28B AUM 24.51% 1-Year Est. Return
HAI
Hennessy Advisors Inc Novato, California $3.13B AUM 77.26% 1-Year Est. Return

Arlington Partners's GSK Position: Q2 2026 in Review

Arlington Partners increased its GSK (GSK) stake by 23% in Q2 2026, buying an estimated $53.2K and bringing the position to 5,388 shares worth $282K. The position accounts for 0.51% of the portfolio, ranked #15.

Arlington Partners first reported a position in GSK in Q4 2018 and has held it in 12 quarters since. The position peaked at $5.43M in Q3 2025. 161 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Arlington Partners held 5,388 shares of GSK worth $282K as of Q2 2026.
  • Arlington Partners bought 1,006 GSK shares in Q2 2026, an estimated $53.2K.
  • GSK made up 0.51% of Arlington Partners's portfolio in Q2 2026, its #15 holding.
  • Arlington Partners first reported a position in GSK in Q4 2018 and has held it in 12 quarters since.
  • Arlington Partners's GSK position peaked at $5.43M in Q3 2025.
  • 161 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Arlington Partners's 13F filing for Q2 2026, filed 7 Jul 2026.